Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 5.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,394 shares of the medical research company’s stock after selling 9,422 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Charles River Laboratories International were worth $36,499,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. VisionPoint Advisory Group LLC grew its position in Charles River Laboratories International by 105.7% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 74 shares in the last quarter. Operose Advisors LLC acquired a new position in Charles River Laboratories International in the 3rd quarter valued at about $42,000. Brown Brothers Harriman & Co. grew its position in Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 95 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth about $62,000. Finally, Bruce G. Allen Investments LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth about $70,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Argus boosted their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. The Goldman Sachs Group assumed coverage on Charles River Laboratories International in a research report on Thursday, June 6th. They set a “buy” rating and a $290.00 price objective for the company. Robert W. Baird lowered their price objective on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, May 10th. StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th. Finally, TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $256.38.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $211.60 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The stock has a 50 day moving average of $222.48 and a two-hundred day moving average of $232.31. The stock has a market cap of $10.90 billion, a P/E ratio of 24.89, a P/E/G ratio of 1.98 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares in the company, valued at $5,282,953.72. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.30% of the stock is owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).